Commercial CVS obesity drug deal puts Lilly on equal footing with Novo BioPharma DiveThe agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.Metabolic & GLP-1Read full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioPharma Dive The agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. Metabolic & GLP-1 Read full story Post navigation Previous: France ‘first EU country to cover obesity drugs’Next: GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’ Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026